{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["66(2)"],"submitter":["Jurin I"],"pubmed_abstract":["<h4>Aim</h4>To assess the relative efficacy of dapagliflozin and empagliflozin in routinely treated chronic heart failure (CHF) patients.<h4>Methods</h4>Data from a registry of prevalent and incident CHF patients were used to set up cohorts (new-user design) of patients started on dapagliflozin or empagliflozin in addition to other guideline-directed therapy. Cohorts were mutually balanced on a range of characteristics, and were assessed for the incidence of a composite of all-cause death/major adverse cardiac events (primary outcome) over the initial 6 months of treatment, and for New York Heart Association (NYHA) functional class at 6 months (secondary outcome). Frequentist and Bayes estimates were generated for the dapagliflozin vs empagliflozin comparison.<h4>Results</h4>In both preval"],"journal":["Croatian medical journal"],"pagination":["135-152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12093124"],"repository":["biostudies-literature"],"pubmed_title":["Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis."],"pmcid":["PMC12093124"],"pubmed_authors":["Pavlovic N","Rudan D","Manola S","Hadzibegovic I","Radic M","Jurin I","Trkulja V","Jurin H"],"additional_accession":[]},"is_claimable":false,"name":"Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis.","description":"<h4>Aim</h4>To assess the relative efficacy of dapagliflozin and empagliflozin in routinely treated chronic heart failure (CHF) patients.<h4>Methods</h4>Data from a registry of prevalent and incident CHF patients were used to set up cohorts (new-user design) of patients started on dapagliflozin or empagliflozin in addition to other guideline-directed therapy. Cohorts were mutually balanced on a range of characteristics, and were assessed for the incidence of a composite of all-cause death/major adverse cardiac events (primary outcome) over the initial 6 months of treatment, and for New York Heart Association (NYHA) functional class at 6 months (secondary outcome). Frequentist and Bayes estimates were generated for the dapagliflozin vs empagliflozin comparison.<h4>Results</h4>In both preval","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-07-15T14:37:43.962Z","creation":"2026-07-06T03:08:52.793Z"},"accession":"S-EPMC12093124","cross_references":{"pubmed":["40343436"]}}